Announced Wed, 13 May · 18:14 IST

Audited Financial Statements for the Quarter and Year ended 31.03.2026

Revenue DeclinePat NegativeResults RestatedExceptional ItemEmphasis Of MatterResults View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-3.2%1-day move
₹6.20
prior close
₹5.90
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.7+1.5+1.5+1.4-3.2-4.8-5.6-7.3-7.3-9.7-14.4-4.8-8.1
Up moveDown movePending
AI summary

Arunjyoti Bio Ventures reported a net loss of Rs 453.61 lakhs for FY26, significantly worse than the loss of Rs 27.62 lakhs in FY25. Revenue from operations declined marginally to Rs 2,775.44 lakhs from Rs 2,788.41 lakhs in the previous year. The company recorded exceptional write-offs of Rs 273.65 lakhs, comprising bad debts (Rs 170.93 lakhs) and advances to vendors (Rs 102.72 lakhs). Additionally, inventory write-off of Rs 241.18 lakhs due to operational bottlenecks was recognized. Prior period errors related to deferred tax were corrected, requiring restatement of comparative figures as per Ind AS 8. The auditor issued an unmodified opinion with two emphasis of matter notes regarding the deferred tax restatement and the write-offs.

Likely market impact

The significantly higher losses and large write-offs indicate operational and financial stress. Shareholders should be cautious as the company posted a loss per share of Rs 0.29 for FY26 compared to Rs 0.01 in FY25, and total equity declined from Rs 3,325.42 lakhs to Rs 2,871.81 lakhs.